Marijuana use among adolescents is associated with deleterious alterations in mature BDNF.
Brain Derived Neurotrophic Factor (BDNF)
Marijuana
adolescent
brain development
smoking
Journal
AIMS public health
ISSN: 2327-8994
Titre abrégé: AIMS Public Health
Pays: United States
ID NLM: 101635098
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
08
2018
accepted:
21
10
2018
entrez:
2
4
2019
pubmed:
2
4
2019
medline:
2
4
2019
Statut:
epublish
Résumé
With increases in marijuana use and legalization efforts, it is imperative to establish its impact on the developing brain. Therefore, we investigated whether exposure to marijuana alters brain derived neurotropic-factor (BDNF), given its critical role in brain development and plasticity. We then examined whether onset age of cannabis use was associated with more severe changes. A single site, cohort study following 500 urban healthy American adolescents. Changes in plasma m-BDNF levels were longitudinally assessed, and a multi-method approach was implemented to ascertain marijuana use. Multivariate and general linear model (GLM) regression modeling were utilized to test the main hypothesis, controlling for confounders. Group-based trajectory modeling identified four distinct groups, characterized by naive (60% control), starters (14%), chronic users (20%), and experimenting/quitters (6%). Compared to controls, those initiating marijuana use had similar pre-existent m-BDNF (1939.2 ± 221 vs. 2640.7 ± 1309 ng/ml, This is the first study demonstrating BDNF alterations were not a precondition. Rather, BDNF alteration was secondary to marijuana use, serving as cautionary evidence of marijuana's deleterious effects. Findings suggest that when marijuana use escalates, the BDNF pathway becomes more deregulated. Analyses confirm that age of marijuana use onset influences the magnitude of these changes.
Sections du résumé
BACKGROUND
BACKGROUND
With increases in marijuana use and legalization efforts, it is imperative to establish its impact on the developing brain. Therefore, we investigated whether exposure to marijuana alters brain derived neurotropic-factor (BDNF), given its critical role in brain development and plasticity. We then examined whether onset age of cannabis use was associated with more severe changes. A single site, cohort study following 500 urban healthy American adolescents. Changes in plasma m-BDNF levels were longitudinally assessed, and a multi-method approach was implemented to ascertain marijuana use. Multivariate and general linear model (GLM) regression modeling were utilized to test the main hypothesis, controlling for confounders.
RESULTS
RESULTS
Group-based trajectory modeling identified four distinct groups, characterized by naive (60% control), starters (14%), chronic users (20%), and experimenting/quitters (6%). Compared to controls, those initiating marijuana use had similar pre-existent m-BDNF (1939.2 ± 221 vs. 2640.7 ± 1309 ng/ml,
CONCLUSIONS
CONCLUSIONS
This is the first study demonstrating BDNF alterations were not a precondition. Rather, BDNF alteration was secondary to marijuana use, serving as cautionary evidence of marijuana's deleterious effects. Findings suggest that when marijuana use escalates, the BDNF pathway becomes more deregulated. Analyses confirm that age of marijuana use onset influences the magnitude of these changes.
Identifiants
pubmed: 30931339
doi: 10.3934/publichealth.2019.1.4
pii: publichealth-06-01-004
pmc: PMC6433615
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4-14Déclaration de conflit d'intérêts
Conflict of interest: The authors declare no conflict of interest.
Références
J Neurobiol. 1999 Oct;41(1):127-34
pubmed: 10504200
Ann Epidemiol. 2001 Feb;11(2):145-53
pubmed: 11164131
Psychiatry Res. 2002 Mar 15;109(2):143-8
pubmed: 11927139
Thromb Haemost. 2002 Apr;87(4):728-34
pubmed: 12008958
Synapse. 2002 Aug;45(2):134-42
pubmed: 12112406
BMJ. 2002 Nov 23;325(7374):1212-3
pubmed: 12446537
Neuron. 2003 Aug 28;39(5):735-8
pubmed: 12948441
Proc R Soc Med. 1965 May;58:295-300
pubmed: 14283879
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10827-32
pubmed: 15249684
Addiction. 2004 Oct;99(10):1333-41
pubmed: 15369572
Neurosci Lett. 2004 Nov 16;371(1):79-83
pubmed: 15500971
Curr Opin Pharmacol. 2005 Feb;5(1):20-5
pubmed: 15661621
J Neurochem. 2005 May;93(4):802-11
pubmed: 15857384
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19115-20
pubmed: 16357196
Nat Neurosci. 2006 Jun;9(6):735-7
pubmed: 16680163
Acta Psychiatr Scand. 2008 Sep;118(3):209-13
pubmed: 18452569
Eur Neuropsychopharmacol. 2008 Dec;18(12):882-7
pubmed: 18774699
Psychopharmacology (Berl). 2009 Mar;202(4):569-78
pubmed: 18807247
Science. 2009 Jun 26;324(5935):1732-4
pubmed: 19478142
Brain Res. 2010 Feb 16;1314:183-93
pubmed: 19732758
Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53
pubmed: 20604989
J Neurosci. 2010 Aug 11;30(32):10727-33
pubmed: 20702703
Am J Med Genet B Neuropsychiatr Genet. 2011 Apr;156B(3):363-9
pubmed: 21305693
Mol Psychiatry. 2012 Jun;17(6):584-96
pubmed: 21894152
Int J Pept. 2011;2011:654085
pubmed: 21966294
Drug Test Anal. 2013 Jan;5(1):62-7
pubmed: 23169764
Curr Pharm Des. 2014;20(13):2186-93
pubmed: 23829363
Ther Adv Psychopharmacol. 2012 Dec;2(6):241-54
pubmed: 23983983
Front Behav Neurosci. 2013 Oct 21;7:149
pubmed: 24155701
J Neurosci. 2014 Apr 16;34(16):5529-38
pubmed: 24741043
JAMA. 2014 Jun 25;311(24):2475-6
pubmed: 24870206
JAMA Pediatr. 2014 Sep;168(9):822-8
pubmed: 25070067
Behav Brain Res. 2015 Feb 15;279:240-54
pubmed: 25449839
J Neurosci. 2015 Jan 28;35(4):1505-12
pubmed: 25632127
Transl Psychiatry. 2016 Jan 12;6:e710
pubmed: 26756903
J Neurosci. 2016 Aug 3;36(31):8149-59
pubmed: 27488635
Am J Public Health. 1980 Jun;70(6):604-13
pubmed: 7377436
Brain Res. 1996 Feb 12;709(1):122-301
pubmed: 8869564
Neuropharmacology. 1998 Dec;37(12):1553-61
pubmed: 9886678